EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody–Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism

Yi Jiang iD, Sai Dong, Yang Wang iD

Cancers · 02.02.2025 · 17 (3) · 496

DOI: 10.3390/cancers17030496 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 02.02.2025. Verfasst von Yi Jiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, Capital Clinical Diagnosis and Treatment Technology Research and Transformation Application Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD30 is overexpressed in many T-cell lymphoma (TCL) entities, including subsets of peripheral T-cell lymphomas (PTCL) and cutaneous T-cell lymphomas (CTCL). The antibody–drug conjugate brentuximab vedotin (BV), targeting CD30-positive cells, has been approved for the treatment of relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (sALCL), and primary cutaneous anaplastic large cell lymphoma or mycosis fungoides in patients who have received previous systemic therapy. However, many patients still experience disease progression after BV monotherapy. Extensive efforts have been dedicated to investigating effective combinations of BV. A phase III clinical study demonstrated that the combination of BV with cyclophosphamide, doxorubicin, and prednisone (CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for CD30-positive PTCL. This study led to the approval of BV with CHP as the first-line therapy for CD30-positive PTCL (sALCL in Europe). We summarize the encouraging combination applications of BV in this review. Ongoing studies on combination therapies of BV are also listed, highlighting potential directions for the future application of BV. We focus on dissecting the underlying mechanisms of BV, discussing its effects on both tumor cells and the tumor microenvironment. Exploring resistance mechanisms in TCL provide valuable insights for optimizing BV-based therapies in the future.

Schlagwörter

Stichwörter der Autor:innen

CD30T-cell lymphomasantibody–drug conjugateanticancer combination therapybrentuximab vedotindrug resistancetumor microenvironment

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China.
  • National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China.
  • NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China.
  • The Second Clinical Medical School, Peking University, Beijing 100044, China.
  • Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.

ORCID-Profile: Yi Jiang, Yang Wang

Förderung

  • National Natural Science Foundation of China
  • Capital's Funds for Health Improvement and Research
  • Capital Clinical Diagnosis and Treatment Technology Research and Transformation Application Program of China
  • Capital’s Funds for Health Improvement and Research

Zitieren

APA

Jiang, Y., Dong, S., & Wang, Y. (2025). Antibody–Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism. Cancers, 17(3), 496. https://doi.org/10.3390/cancers17030496

Vancouver

Jiang Y, Dong S, Wang Y. Antibody–Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism. Cancers. 2025;17(3):496. doi:10.3390/cancers17030496

BibTeX
@article{Jiang2025,
  author = {Jiang, Yi and Dong, Sai and Wang, Yang},
  title = {Antibody–Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {496},
  doi = {10.3390/cancers17030496}
}
Kostenlos starten →